• Serve as the clinical pharmacology leader for multiple programs in GondolaBio’s pipeline, defining stage-appropriate PK/PD, exposure–response, and dose-selection strategies to support rapid, high-quality decisions through early proof of concept • Lead clinical pharmacology strategy for first-in-human and early Phase 1/2 studies, including starting dose rationale, dose escalation design, SAD/MAD strategy, and integration of nonclinical and translational data • Design, interpret, and communicate PK/PD, biomarker, and exposure–response analyses to inform dose optimization and go/no-go decisions, in close partnership with Translational and Clinical Development teams • Apply fit-for-purpose pharmacometric and modeling approaches to support early development decisions and regulatory interactions • Partner across functions to support INDs, regulatory interactions, and integrated development plans; clearly communicate clinical pharmacology insights to senior leadership • Oversee external pharmacometrics vendors, CROs, and consultants as needed to ensure timely, high-quality execution